A network biology workflow to study transcriptomics data of the diabetic liver by Martina Kutmon et al.
Kutmon et al. BMC Genomics 2014, 15:971
http://www.biomedcentral.com/1471-2164/15/971
METHODOLOGY ARTICLE Open Access
A network biology workflow to study
transcriptomics data of the diabetic liver
Martina Kutmon1,2*, Chris T Evelo1 and Susan L Coort1
Abstract
Background: Nowadays a broad collection of transcriptomics data is publicly available in online repositories.
Methods for analyzing these data often aim at deciphering the influence of gene expression at the process level.
Biological pathway diagrams depict known processes and capture the interactions of gene products and metabolites,
information that is essential for the computational analysis and interpretation of transcriptomics data.
The present study describes a comprehensive network biology workflow that integrates differential gene expression
in the human diabetic liver with pathway information by building a network of interconnected pathways. Worldwide,
the incidence of type 2 diabetes mellitus is increasing dramatically, and to better understand this multifactorial disease,
more insight into the concerted action of the disease-related processes is needed. The liver is a key player in
metabolic diseases and diabetic patients often develop non-alcoholic fatty liver disease.
Results: A publicly available dataset comparing the liver transcriptome from lean and healthy vs. obese and
insulin-resistant subjects was selected after a thorough analysis. Pathway analysis revealed seven significantly altered
pathways in the WikiPathways human pathway collection. These pathways were then merged into one combined
network with 408 gene products, 38 metabolites and 5 pathway nodes. Further analysis highlighted 17 nodes present
in multiple pathways, and revealed the connections between different pathways in the network. The integration of
transcription factor-gene interactions from the ENCODE project identified new links between the pathways on a
regulatory level. The extension of the network with known drug-target interactions from DrugBank allows for a more
complete study of drug actions and helps with the identification of other drugs that target proteins up- or
downstream which might interfere with the action or efficiency of a drug.
Conclusions: The described network biology workflow uses state-of-the-art pathway and network analysis methods
to study the rewiring of the diabetic liver. The integration of experimental data and knowledge on disease-affected
biological pathways, including regulatory elements like transcription factors or drugs, leads to improved insights and a
clearer illustration of the overall process. It also provides a resource for building new hypotheses for further follow-up
studies. The approach is highly generic and can be applied in different research fields.
Keywords: Transcriptomics, Network biology, Pathway analysis, Type 2 diabetes mellitus, Fatty liver, Non-alcoholic
fatty liver disease, WikiPathways, PathVisio, Cytoscape
Background
Type 2 diabetes mellitus (T2DM) is a metabolic disorder
characterized by chronic hyperglycemia with disturbances
of carbohydrate, lipid and protein metabolism resulting
from defects in insulin secretion, insulin resistance, or
both. Obesity, the excess accumulation of lipids in the
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body, is a major risk factor for T2DM. Metabolism in
the liver, adipose tissue and skeletal muscle is of key
importance for the pathogenesis of T2DM. The current
study focuses on the liver. It is well known that lipid
accumulation in the liver contributes to insulin resis-
tance, hyperglycemia and hyperlipidemia [1]. Hepatic
lipid accumulation is the main characteristic of non-
alcoholic fatty liver disease (NAFLD), and NAFLD is
strongly associated with T2DM. In T2DM, one of the key
liver functions, the postprandial insulin-mediated uptake
of glucose, is impaired [2]. Moreover, gluconeogenesis
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is affected because of the disturbed insulin inhibition of
glucose production [3]. Published studies of gene expres-
sion in liver of patients with NAFLD indicate an increase
in both de novo lipogenesis and lipid oxidation [4,5].
Although NAFLD studies have identified genes, proteins
and processes that are important, not all biological mech-
anisms involved in the human diabetic liver have been
deciphered [6].
Modern technology enables a global analysis of gene
expression in liver tissue. Exploring published transcrip-
tomics datasets available in online repositories revealed
only one transcriptomics study investigating the human
diabetic fatty liver. Pihlajamäki et al. [7] measured gene
expression with microarray technology in liver biopsies
of lean, obese and obese, diabetic subjects. Instead of
only investigating the individual gene expression, current
analysis methods often aim at deciphering biological func-
tions at the process level. Generally, gene set enrichment
analysis and pathway analysis are applied to find biological
processes of interest [8]. Pihlajamäki et al. identified a rela-
tionship between thyroid hormone action and the altered
gene expression pattern. The present study uses state-of-
the-art pathway and network analysis methods to integrate
knowledge of differential gene expression with pathway
information by building a network of interconnected
pathways. The focus shifts from looking at single gene
expression levels to changes on process level and beyond.
Pathway analysis was used to find significantly altered
biological processes. WikiPathways [9] was the database
used to provide the pathway collections for this analy-
sis. Next, network analysis was applied to i) identify the
genes that link the pathways relevant in the diabetic fatty
liver, ii) investigate the transcriptional regulation within
the pathways and iii) identify known drugs that target
genes in the pathways and their effects. The open-source
and widely-used pathway and network visualization and
analysis tools PathVisio [10] and Cytoscape [11] were used
in a comprehensive network biology approach.
Although biological pathways are usually seen as inde-
pendent processes, they do interact with and depend on
each other. Our workflow combines and integrates rele-
vant pathways into one biological network which allows
researchers to study the effects of a disease or treatment
not only in the pathway of interest but also in downstream
or related pathways. Further extending the network with
additional information, like transcription factor (TF) reg-
ulation, provides a more complete picture of complex
biological processes and will promote the understanding
of the mechanisms of diseases.
Methods
Transcriptomics dataset
In this study a published and publicly available transcrip-
tomics dataset generated by Pihlajamäki [7] was used. The
dataset is available from the Gene Expression Omnibus
(accession number GSE15653). This was the only well-
described human transcriptomics dataset on the human
diabetic liver we found in online transcriptomics data
repositories like GEO. 18 individuals, 5 lean and 13 obese,
undergoing elective surgery for obesity or gallstones par-
ticipated in the study. Based on a preoperative oral glu-
cose tolerance test the obese subjects were diagnosed
for T2DM. The percentage of liver fat content was sig-
nificantly (p<0.05) increased in obese, diabetic subjects
compared to lean subjects indicating the development
of NAFLD in these subjects. Gene expression was mea-
sured in surgical liver biopsies from 4 obese subjects, 9
obese subjects with T2DM and 5 lean control subjects
during fasting using Affymetrix Human Genome U133A
microarrays. We selected the 5 lean and 9 obese, diabetic
subjects to study the molecular changes in the diabetic
fatty liver. TheHOMA-IR (homeostatic model assessment
for insulin resistance) shows a significantly higher insulin
resistance in obese, diabetic subjects compared to lean
subjects (p<0.05).
Affymetrix microarray analysis
The raw data for 9 obese, diabetic subjects and 5 lean
control subjects was reanalyzed with ArrayAnalysis.org,
an online microarray quality control and pre-processing
pipeline [12]. The data was normalized using the GC-
RMA method and further evaluated. The quality control
report is provided as Additional file 1.
TheArrayAnalysis.org statisticsmodule uses the Limma
package [13] of R/Bioconductor which applies linear
regression models to make the statistical comparison
between obese, diabetic subjects vs. control lean group.
Genes were considered to be differentially expressed
when their (1) absolute log2 fold change (FC) > 1 and
(2) p-value < 0.05.
Gene ontology analysis
Gene Ontology (GO) analysis was performed using the
GO-Elite web-interface [14] to identify biological pro-
cesses for the differentially expressed genes in the dataset.
The following settings were used: (1) 2000 permuta-
tions, (2) Z-score pruning algorithm, (3) Z-score thresh-
old> 1.96, (4) p-value threshold< 0.05 and (5) minimum
number of changed genes is 3. GO-Elite uses an advanced
ontology pruning algorithm to report a minimally non-
redundant set of results.
Pathway analysis
Pathway analysis was performed in PathVisio 3.1.3 (http://
www.pathvisio.org) to interpret and visualize the molec-
ular changes on a pathway level. The human path-
way collection containing 262 pathways was obtained
from WikiPathways (http://www.wikipathways.org, see
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Additional file 2). An overrepresentation analysis was
performed using differentially expressed genes. The path-
ways are ranked based on a standardized difference score
(z-score) using the expected value and standard devi-
ation of the number of differentially expressed genes
in a pathway under a hypergeometric distribution. A
positive z-score indicates pathways with a greater num-
ber of significantly changed genes than is expected
by chance [15]. Pathways were considered signifi-
cantly changed when (1) Z-score > 1.96, (2) permutated
p-value < 0.05 and (3) minimum number of changed
genes is 3. Additionally, the log2FC and p-value were
visualized on pathways with the visualization module in
PathVisio.
Network analysis
First, all significantly changed pathways were combined
and visualized with Cytoscape 3.1.1. The pathways were
loaded as networks using the WikiPathways app [16]
and an identifier mapping step was performed with the
BridgeDb App [17] to unify the identifiers to Ensembl for
gene products andHMDB formetabolites. By applying the
network merge functionality in Cytoscape the pathways
were combined into one integrated network.
Second, the gene expression data was visualized on the
nodes of the network. Third, the integrated network was
extended with information on transcriptional regulation
derived from the ENCODE project [18] using the CyTar-
getLinker app [19]. Finally, drug-target interactions from
DrugBank version 4 [20] were integrated in the network.
The comprehensive visualization functionality in
Cytoscape was applied to further explore the complex
regulatory mechanisms.
Workflow
The strength of the described workflow is that the tools
can be easily combined and used together. Figure 1 shows
the different steps in the workflow and in each step the
output of one tool can be used as the input of the next
one. The raw Affymetrix sample files were downloaded
from GEO and directly uploaded to ArrayAnalysis.org.
This pipeline performs quality control, normalization and
statistical analysis of microarray data. The result of the
statistical analysis can be used as input for PathVisio with-
out any intermediate steps. The outcome of the pathway
statistics in PathVisio is a list of significantly changed
pathways. The pathways are stored in GPML format
and can be opened in Cytoscape using the WikiPath-
ways app. Using the BridgeDb app, the identifiers of the
pathways can be unified if necessary and the Cytoscape
merge functionality is used to create one large network
from the separate pathways. The CyTargetLinker app then
enables the user to extend the network with regulatory
interactions like drug-target or TF-gene interactions. A
comprehensive description of the workflow can be found
on http://projects.bigcat.unimaas.nl/netbio-workflow/.
Results
A network biology workflow was designed to decipher the
biological processes involved in the human diabetic liver.
The results obtained with pathway and network analysis
will be explained in more detail.
Differential expression
In the selected human diabetic fatty liver dataset 11,878
genes were measured and annotated in both lean
and obese, diabetic subjects. Statistical analysis showed
that 181 genes were differentially expressed (absolute
logFC > 1 and p-value < 0.05), of these were 118 up-
regulated and 63 down-regulated in the obese, diabetic
subjects compared to the lean control group. 68 of the
up-regulated and 17 of the down-regulated genes have
known functions in biological pathways (see Additional
file 3: Tables S1 and S2).
The GO analysis was performed with GO-Elite and
showed relevant processes for T2DM being over-repre-
sented, e.g. triglyceride metabolic process (GO:0006641),
cholesterol metabolic process (GO:0008203), glucose me-
tabolic process (GO:0006006), response to glucose sti-
mulus (GO:0009749), cholesterol homeostasis (GO:004
2632) and complement activation, classical pathway
(GO:0006958). Furthermore, processes related to one-
carbon metabolism, humoral immune response, protein-
lipid complex subunit organization and organic anion
transport were found.
Pathway analysis
Biological processes in which differentially expressed
genes are enriched were identified by performing path-
way analysis in PathVisio. The statistical analysis resulted
in seven significantly changed pathways (Z-score > 1.96,
p-value < 0.05, minimum of three changed genes) (see
Table 1). Most of these pathways are processes relevant for
T2DM but there are also some bigger pathways included,
like Proteasome Degradation or Adipogenesis. To illus-
trate the visualization of the analyzed gene expression
data two pathways known to be important in drug treat-
ment of T2DM were selected, i.e. the AMPK Signaling
and the Statin pathway (Figure 2A and 2B). Images of
all altered pathways are provided in Additional file 4:
Figure S1–S7.
In the AMPK Signaling pathway the gene expres-
sion of the upstream regulating kinases of AMPK, i.e,
CAMKK, LKB1, MO25 and STRADA, were significantly
up-regulated. Moreover, the expression of the glucose
transport protein 4 (GLUT4) is significantly increased
together with an increase in the GLUT4 enhancer factor
(GEF; p-value = 0.057). Most downstream AMPK targets
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Figure 1 Transcriptomics network biology workflow. The described workflow uses four different tools that can be easily connected by taking
the output of one tool and importing it in the next tool. No intermediate steps are required.
were up-regulated, i.e., HNF4A, SREBF1, eEF2, TSC2, p21
and some are down-regulated, like PFK2 and TSC1.
In the Statin pathway the inhibitory action of statin,
a cholesterol-lowering drug, on HMG-CoA reductase
(HMGCR) is depicted. The expression of HMGCR
remains unaltered in the diabetic fatty liver compared to
lean controls. Moreover, cholesterol synthesis is described
in the pathway and almost all differentially expressed




Pathway analysis revealed seven pathways with a
Z-score > 1.96 (see Table 1) which were then com-
bined into one biological network and analyzed in the
network visualization and analysis tool Cytoscape. The
created network contains 642 edges connecting 580
nodes, consisting of 408 gene products, 38 metabolites
and 5 pathway nodes. 129 nodes are visualized as very
small nodes to represent groups and complexes as well
as complex interactions in the pathways. Pathways from
WikiPathways can contain pathway nodes that link to
other pathways. The created network has therefore links
to five other pathways: Glycolysis (WP534), DNA Repair
(WP1805), Fatty Acid Oxidation (WP143), Fatty Acid
Synthesis (WP357) and Apoptosis (WP254).
A figure of the complete network is available in Additional
file 5: Figure S8. Fourteen genes in the network are sig-
nificantly up regulated in obese, diabetic subjects includ-
ing three genes linking two or more pathways such as
AGPAT2, CDKN1A and SREBF1. Seven genes, all present
in only one pathway, are significantly down regulated.
Figure 3 shows how fourteen genes and three metabo-
lites are linking two or more of the selected pathways to
each other. The transcriptomics dataset comparing obese,
Table 1 Seven pathways changed in the diabetic liver
Pathway Z-score P-value # Genes Genes
Triacylglyceride Synthesis 3.78 0.001 3 / 19 ↑ AGPAT2, GPD1, DGAT1
Proteasome Degradation 3.32 0.006 5 / 53 ↑RPN1, PSMB3, HLA-B, HLA-E, HLA-J
Statin Pathway 3.10 0.006 3 / 25 ↑DGAT1, APOA4, CYP7A1
Fluoropyrimidine Activity 2.84 0.013 3 / 28 ↑SLC22A7
↓ABCG2, DPYD
Pathogenic Escherichia coli infection 2.76 0.011 4 / 46 ↑ ARPC1A, ARPC1B, ACTB
↓ ROCK1
Adipogenesis 2.41 0.016 7 / 121 ↑ SREBF1, CDKN1A, NR1H3, PNPLA3, AGPAT2
↓ CISD1, ZMPSTE24
AMPK Signaling 2.38 0.029 4 / 54 ↑ SREBF1, P21
↓ LEPR, PFKFB3
Pathway statistics in PathVisio revealed seven significantly altered pathways (Z-score> 1.96, P-value< 0.05, minimum of 3 changed genes). The number of genes
(# Genes) represent the number of differentially expressed genes in the pathway compared to the total number of measured genes in the pathway. The arrows
indicate up ↑ and down-regulation ↓.
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Figure 2 Visualization of two pathways relevant for drug treatment of T2DM. Gene expression is visualized on (A) AMPK Signaling pathway,
http://www.wikipathways.org/instance/WP1403 and (B) Statin pathway, http://www.wikipathways.org/instance/WP430 from WikiPathways. The
visualization of the gene product boxes in the pathways is split into two parts, (1) the log2 FC in the left part of the box (blue is down-regulated over
white is not changed to red is up-regulated) and (2) the p-value in the right part of the box (green when significant). Pathway elements including
metabolites that have not been measured in the selected dataset are gray.
diabetic subjects with lean subjects is visualized in the net-
work. The log2FC is indicated by a color gradient on the
nodes and significance (p-value < 0.05) is represented by
a light-green border. Nodes including metabolites without
a measurement in the dataset are colored gray.
In the liver of obese, diabetic subjects, the gene expres-
sion of three of the linker genes, i.e. AGPAT2, CDKN1A
and SREBF1, is significantly (p < 0.05) up-regulated.
AGPAT2 is an enzyme that plays an important role in the
production of glycerophospholipids and triacylglycerols.
Figure 3 Nodes linking the seven significantly changed pathways. Each pathway is represented as a yellow rounded rectangle. Gene products
and metabolites are visualized as ellipses and octagons, respectively. The transcription dataset is visualized on the gene nodes in the network using
a color gradient from blue (down-regulated) over white (not changed) to red (up-regulated). Nodes with a significant p-value (< 0.05) have a
light-green border color. Most nodes linking multiple pathways are either up-regulated (e.g. SREBF1, CDKN1A, AGPAT2) or not altered significantly
(e.g. LPL, HMGCR).
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It is known to be relevant to the liver and development
of hepatic steatosis [21]. CDKN1A is a potent cell cycle
inhibitor important for the induction and maintenance
of cellular senescence. SREBF1 is a TF regulating genes
required for glucose and fatty acids metabolism and lipid
synthesis. Studies showed a clear link between muta-
tions in CDKN1A and SREBF1 and the risk of developing
NAFLD [22,23] strengthening the involvement of these
genes in diabetic fatty liver. A table describing the func-
tion, gene expression and their involvement in NAFLD
and diabetes for all linking genes is provided in Additional
file 6: Table S3.
Extension with transcriptional regulation
The integrated network was extended with transcriptional
regulation to obtain a better insight in how biological
processes affected in the human fatty liver are regulated.
The CyTargetLinker app in Cytoscape was used to extend
the network with proximal TF-target interactions from
the ENCODE project [24]. The app identified sixteen
nodes in the network as TFs, most of which are nodes
present in only one pathway, except for SREBF1. All TFs
are present in either the AMPK Signaling pathway or the
Adipogenesis pathway.
Figure 4 shows a network containing the sixteen TFs as
diamonds and 90 of their targets which are present in one
of the selected seven pathways. The interactions in this
network are not present in the pathways but have been
reported in the ENCODE regulatory network derived
by Gerstein et al. [18]. In the initial network, pathway
elements were not present in more than three out of seven
pathways, however with the CyTargetLinker app, TFs were
identified that target genes in up to six out of seven dif-
ferent pathways, like SP1 or HNF4A. This approach also
found some TFs regulating other TFs (highlighted as light-
blue edges) and discovered typical network motifs like
feed-forward loops (e.g. STAT1 → STAT3 → STAT2 →
STAT1) or self-regulation (e.g. SP1, GATA2 or CEBPB).
Three of the TFs in the network are up-regulated in obese,
diabetic subjects, SREBF1 (log2FC: 1.05, p-value: 0.03),
STAT3 (log2FC: 0.88, p-value: 0.008) and CEBPB (log2FC:
0.41, p-value: 0.01). All three have been reported to play a
role in the development of NAFLD [25-27].
Extension with drug-target information
CyTargetLinker provides a regulatory interaction network
for drug-target interactions from DrugBank. The com-
bined network was extended only with approved drugs
Figure 4 TF regulation in the diabetic fatty liver pathways. Using CyTargetLinker, sixteen TFs have been identified in the seven pathways. TFs
are visualized as rounded rectangles and their target genes as circles colored based on their presence in different pathways. 56 genes are targeted
by only one TF and 33 genes are targeted by 2 or more TFs. Light-blue edges indicate regulation of TFs by other TFs.
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Figure 5 Significant amount of antidiabetic drugs targeting gene products in the network. The network has been extended with drug-target
interactions from DrugBank 4 using CyTargetLinker. Nodes present in only one pathway and not targeted by any drugs have been grouped in
pathway nodes (yellow rounded rectangles). Drugs targeting genes in the network are indicated as blue rectangles, drugs associated with diabetes
are colored in red, micronutrients/dietary supplements in green, drugs related to immune response in orange and anticholesteremic agents in
purple. Diabetes related drugs target 7 gene products in the network: INSR (8 drugs), PPARG (5 drugs), RB1 (2 drugs), ABCA1 (1 drug), CPT1A (1 drug),
PRKAA1 (1 drug), PRKAB1 (1 drug).
leaving out the ones that are withdrawn or experimental.
In total 280 drugs were added targeting 76 gene products
in the pathways, see Figure 5. Based on the categories used
in DrugBank the drugs associated with the treatment of
diabetes (= antidiabetic and hypoglycemic agents; colored
in red), dietary supplements/micronutrients (colored in
green), immune response related (colored in orange) and
anticholesteremic agents (colored in purple) are high-
lighted in Figure 5. In the extended network, the amount
of drug targets related to diabetes is significantly higher
than random (see Additional file 7: Figures S9 and S10).
The insulin receptor (INSR) is targeted by nine drugs
of which eight are categorized in DrugBank as antidia-
betic and/or hypoglycemic agents and the ninth, Mecaser-
min, is an insulin-like growth factor used for long-term
treatment of growth failure in children with severe pri-
mary IGF-1 deficiency [28]. The INSR is activated by
insulin binding and after activation it phosphorylates and
thereby activates insulin receptor substrate 1 (IRS1) which
in turn activates the PI3-kinase and AKT signalling path-
ways. Insulin is a natural hormone produced by beta cells
in the pancreas and has many functions, e.g. promotion
of cellular uptake of glucose and energy storage via glyco-
genesis. T2DM patients who are unable to control their
glucose levels can be treated with insulin analogues, like
Insulin Aspart, Detemir or Glargine and these are indeed
drugs targeting the INSR in the drug-target network.
Furthermore, two diabetes related drugs, Phenformin
and Metformin, target the two subunits of AMPK,
PRKAA1 and PRKAB1. Both subunits are also activated
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by a member of the adenine nucleotide family, adeno-
sine monophosphate (AMP), which by DrugBank is
categorized as dietary supplement andmicronutrient. The
network shows that several hypoglycemic agents, like
Rosiglitazone, Glipizide or Pioglitazone, are known to tar-
get PPARG, a receptor which regulates fatty acid storage
and glucose metabolism. All these drugs are known to be
prescribed to T2DM patients depending on the state of
the disease.
Discussion
It has been shown that insulin resistance conditions like
obesity and T2DM are strongly associated with the accu-
mulation of lipids in the liver, which is one of the main
characteristics of NAFLD [29,30]. Although it is known
that impaired substrate metabolism is involved in the
development of the fatty liver in T2DM, the exact mecha-
nisms remain unclear. In this study, we applied a network
biology approach to investigate the molecular mecha-
nisms in the diabetic fatty liver.
Biological pathway information is useful for better
understanding the mechanisms affected by disease. As
illustrated in this study, researchers can investigate the
pathways in diseased subjects compared to control sub-
jects to gain more insights into the causes of a disease
and the mechanisms of disease progression. Although
pathway collections cover many well-described biologi-
cal mechanisms, they are incomplete, resulting in a bias
towards well-studied processes. Nevertheless, pathway
databases are growing and pathway analysis has proven
itself as a valid and intuitive first step in the analysis pro-
cess. Wiki-based community curated pathway databases
like WikiPathways reduce the barrier to participation in
pathway curation and allow experts to add new findings
immediately to the pathway diagrams.
While standard pathway analysis investigates each path-
way individually, biological processes are not indepen-
dent but rather interact with and influence each other.
Therefore it is relevant to investigate the links between
them as well as shared regulatory mechanisms. This study
describes a workflow for further exploring the interplay
between pathways involved in the human fatty liver by
connecting them in a biological network and extending
them with additional knowledge on TF regulation and
drug targeting.
Pathway analysis demonstrated that Triacylglyceride
Synthesis and Adipogenesis are significantly altered in
obese, diabetic subjects with a fatty liver compared to
the lean control group. The pathway analysis was per-
formed using gene expression measured in liver biop-
sies. Although the biopsies mostly consist of hepatocytes
also other cells like immune, vascular and fat cells are
present. Interestingly, two pathways related to drug treat-
ment in T2DM (i.e. the AMPK signaling pathway and
the Statin pathway) are among the significantly altered
pathways.
AMPK is known as the metabolic regulator, and its
activation influences many metabolic processes [31].
Under catabolic situations, like in a fasted state, AMPK
is activated, thereby increasing glycolysis and FA beta-
oxidation and decreasing FA synthesis [32]. AMPK activa-
tion requires both AMP binding and phosphorylation in
the catalytic alpha subunit. Phosphorylation of AMPK is
accomplished by the upstream regulators, CAMKK2 and
LKB1 in complex withMO25 and STRADA [33]. The gene
expression of all upstream regulators of AMPK are signif-
icantly up-regulated showing that the AMPK pathway is
over-represented in the human diabetic liver.
In the Statin pathway, the expression of genes involved
in cholesterol and triacylglycerol production (DGAT1,
CYP7A1, SCARB1, LCAT and APOA4) are all signifi-
cantly up-regulated in the diabetic liver in humans. These
findings indicate that hepatic lipid accumulation is facili-
tated by an increased expression of these genes.
Regulatory elements like TFs are often not included in
pathway diagrams in order to keep the diagrams compre-
hensible. Nevertheless, as this study confirms, TFs play
a crucial role in the understanding of complex diseases
since they often regulate multiple pathways simultane-
ously. Our analysis shows that TFs can be considered
as additional links between pathways, and adding the
regulatory interactions increases the overall connectivity
of the network significantly. Typical TF network motifs
(e.g. feed-forward loops, single input module or self-
regulation) can be identified using standard network
algorithms.
Hepatocyte nuclear factor 4-alpha (HNF4A) is an essen-
tial TF in the extended regulatory network (see Figure 4)
which is regulated by two TFs (i.e. PPARGC1A and SP1)
and regulates genes in 6 out of 7 pathways (not in the E.coli
infection pathway). HNF4A is a nuclear receptor (NR),
which is a key regulator of the liver cell function, is a sen-
sor of inflammation and is known to regulate genes in lipid
and glucose metabolism [34].
Furthermore, CyTargetLinker revealed 93 additional
TFs, not yet present in one of the pathways, which target
212 nodes in the network. TFs generally regulate multiple
targets, and thus more than 800 regulatory interactions
have been added. Two hub TFs targeting more than 35
genes in the pathways are CTCF and EP300. CTCF is a
general TF that has been reported tomediate the effects of
insulin on glucagon expression and therefore is a possible
new target for diabetes treatment [35]. EP300 is a general
TF that regulates cell growth and division and has been
reported as a key participant in hepatic steatosis [27].
The extension of the network with drug-target informa-
tion resulted in a higher number of known drugs used
to treat T2DM than expected which confirms the validity
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of the approach described in this study. The network can
be used to show where drug targets are located and what
effect can be expected in a pathway. It might be possi-
ble to identify other drugs with similar pharmacological
effects or advantageous drug combinations when target-
ing two positions in the network to get a stronger effect of
the treatment, e.g. combination of Glipizide (PPARG) and
Metformin (AMPK). It might also be used to identify new
drugs targeting pathway elements upstream, downstream
or even parallel to the currently used targets.When study-
ing the effects of drugs on a pathway, the grouped pathway
nodes in Figure 5 can be further expanded to view the
complete pathway and its interactions.
Besides the diabetes related drugs, there are many other
drugs known to target genes in the selected pathways.
HMGCR, a highly targeted gene product, is part of the
Statin pathway depicted in Figure 2A and is targeted by
seven drugs, all belonging to the statin family. This drug
family has a cholesterol lowering effect and is often used in
combination with anti-diabetic drugs [36]. Furthermore,
three gene products in the network (ADRA1A, ADRA1B
and NR3C1) are highly targeted by more than 40 drugs.
ADRA1A and ADRA1B are members of a subfamily of
the G protein-coupled receptors (GPCRs), and there are
several studies investigating the potential of GPCRs for
the treatment of T2DM [37,38]. NR3C1 is part of the NR
superfamily of TFs that are known to play a role in the
development and adaptations of liver diseases. NRs are
also suggested as potential drug targets for the treatment
of diabetes and NAFLD [39].
In general, the described workflow can be applied to dif-
ferent datasets, diseases and pathway collections. It also
allows the analysis of multiple datasets together by per-
forming separate pathway analyses and then combining
the pathway results in one integrated network. The inte-
gration of pathway information into the network allows
researchers to investigate the downstream effects of drugs
and contributes to the identification of other treatment
possibilities. Also, the link with other pathways that are
affected or not affected by the disease state is important
for predicting possible side effects of a drug. Includ-
ing the information about the effects of other drugs in
linked or related pathways can help to identify potential
interferences with the efficacy and efficiency of a drug.
Conclusions
In this study we demonstrated how pathway analysis
results, which are often considered a final step in the
biological interpretation of transcriptomics data, can be
used and combined in a biological network to gain more
insights in the interplay and relation between processes.
Instead of starting with a large protein-protein interaction
network and finding the important parts in it, we believe
that building the networks based on relevant pathways
can be another very useful approach to start the investi-
gation. Also the inclusion of all elements present in the
pathway provides a framework which can integrate dif-
ferent types of omics-data, like omics techniques applied
to any gene product (transcriptomics, proteomics, etc)
as well as metabolomics or fluxomics. The biological
interpretation might be more straight-forward because it
builds on the pathway diagrams which are usually intuitive
and well studied.
Regulation by TFs or drugs does not only have effects
on one pathway but also has effects on downstream pro-
cesses. This integration leads to improved insight and
also a much clearer illustration of the overall process, and
the most important elements. Inclusion of information
about drugs and micronutrients and their targets makes
the mode of action of currently used compounds more
understandable and can be useful to suggest drug repo-
sitioning and new drugs or micronutrient related lifestyle
interventions.
The tools used in this study, especially PathVisio,
Cytoscape and CyTargetLinker, facilitated the data inte-
gration, visualization and interpretation immensely.
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